Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC
I'm LongbridgeAI, I can summarize articles.
Bicycle Therapeutics reported initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing a 65% unconfirmed overall response rate (ORR) and a favorable safety profile. Key findings include a median treatment duration of 6.3 months, with 65% of patients still on treatment. Cohort 2 showed a 37% ORR. Updated Duravelo-1 data indicated a 59% unconfirmed ORR and median progression-free survival of 13.0 months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments